Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling
- PMID: 17376027
- DOI: 10.1146/annurev.biochem.76.060305.150444
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling
Abstract
Although cyclic nucleotide phosphodiesterases (PDEs) were described soon after the discovery of cAMP, their complexity and functions in signaling is only recently beginning to become fully realized. We now know that at least 100 different PDE proteins degrade cAMP and cGMP in eukaryotes. A complex PDE gene organization and a large number of PDE splicing variants serve to fine-tune cyclic nucleotide signals and contribute to specificity in signaling. Here we review some of the major concepts related to our understanding of PDE function and regulation including: (a) the structure of catalytic and regulatory domains and arrangement in holoenzymes; (b) PDE integration into signaling complexes; (c) the nature and function of negative and positive feedback circuits that have been conserved in PDEs from prokaryotes to human; (d) the emerging association of mutant PDE alleles with inherited diseases; and (e) the role of PDEs in generating subcellular signaling compartments.
Similar articles
-
Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals.Prog Brain Res. 2009;179:67-73. doi: 10.1016/S0079-6123(09)17908-6. Epub 2009 Nov 20. Prog Brain Res. 2009. PMID: 20302819 Review.
-
Phosphodiesterases in the central nervous system.Handb Exp Pharmacol. 2009;(191):71-92. doi: 10.1007/978-3-540-68964-5_5. Handb Exp Pharmacol. 2009. PMID: 19089326 Review.
-
Overview of PDEs and their regulation.Circ Res. 2007 Feb 16;100(3):309-27. doi: 10.1161/01.RES.0000256354.95791.f1. Circ Res. 2007. PMID: 17307970 Review.
-
Cyclic nucleotide specific phosphodiesterases of Leishmania major.BMC Microbiol. 2006 Mar 8;6:25. doi: 10.1186/1471-2180-6-25. BMC Microbiol. 2006. PMID: 16522215 Free PMC article.
-
Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.Exp Biol Med (Maywood). 2007 Jan;232(1):38-51. Exp Biol Med (Maywood). 2007. PMID: 17202584 Review.
Cited by
-
The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.Front Endocrinol (Lausanne). 2022 Oct 13;13:1024423. doi: 10.3389/fendo.2022.1024423. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36313756 Free PMC article. Review.
-
Phosphodiesterase 4D activity in acrodysostosis-associated neural pathology: too much or too little?Brain Commun. 2024 Jun 29;6(4):fcae225. doi: 10.1093/braincomms/fcae225. eCollection 2024. Brain Commun. 2024. PMID: 38983619 Free PMC article. Review.
-
Phosphodiesterase 4D: an enzyme to remember.Br J Pharmacol. 2015 Oct;172(20):4785-9. doi: 10.1111/bph.13257. Epub 2015 Sep 22. Br J Pharmacol. 2015. PMID: 26211680 Free PMC article. Review.
-
Cross Talk Between Cyclic Nucleotides and Calcium Signaling Pathways in Plants-Achievements and Prospects.Front Plant Sci. 2021 Feb 16;12:643560. doi: 10.3389/fpls.2021.643560. eCollection 2021. Front Plant Sci. 2021. PMID: 33664763 Free PMC article. Review.
-
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications.J Endocrinol Invest. 2016 Feb;39(2):143-51. doi: 10.1007/s40618-015-0340-5. Epub 2015 Jun 28. J Endocrinol Invest. 2016. PMID: 26122487 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources